retatrutide clinical trial results safety Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide produces up to 30.3%

This gentle daily supplement supports steady digestion, regularity, and microbiome health as your body adjusts to new eating patterns

Wondering why semaglutide can make you tired

Designed to boost your bodys own bile by providing a more water-soluble form of bile salt than most people with compromised gallbladders or bile make on their own

Adjusted PAT for the year surged 50% to 10,455 million, with Q4 adjusted PAT rising 97% to 3,667 million

The GLP-1 Revolution: The Companies Dominating One of Pharma's Fastest-Growing Markets The global GLP-1 market has transformed from a niche diabetes segment into one of the most valuable therapeutic categories in pharmaceutical history